Research location
Cremona
CR, Italy
Advertisement
Research activity in Cremona
CR, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cremona
16 linked trials · page 1 of 1Neurosurgical Outcome NetworkNCT06724029 · 2022-12-05 · 1 site observation
RECRUITING
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · 2018-02-02 · 1 site observation
TERMINATED
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
BLITZ Heart FailureNCT03661060 · 2017-03-08 · 1 site observation
COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation EventNCT02661217 · 2016-02-12 · 1 site observation
COMPLETED
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT02278120 · 2014-11-20 · 1 site observation
COMPLETED
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal WomenNCT01923168 · 2014-03-11 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFNCT01870778 · 2013-10-02 · 1 site observation
COMPLETED
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiNCT01633060 · 2012-10-03 · 1 site observation
TERMINATED
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorNCT01610284 · 2012-08-07 · 1 site observation
COMPLETED
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate CancerNCT01212991 · 2010-09-16 · 1 site observation
COMPLETED
Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast CancerNCT00958971 · 2009-07-01 · 1 site observation
COMPLETED
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart FailureNCT00894387 · 2009-05-01 · 1 site observation
COMPLETED
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHFNCT00336336 · 2002-08-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.